2026 approvals, clinical data, and licensing deals are advancing subcutaneous biologics, reducing patient burden, and reshaping biopharma drug strategy.
News|Articles|June 2, 2001
- Pharmaceutical Technology-06-02-2001
- Volume 25
- Issue 6
A Systematic Evaluation of the Compression and Tablet Characteristics of Various Types of Lactose and Dibasic Calcium Phosphate
Author(s)Ruey-ching (Richard) Hwang, PhD
Using formulations containing various types of lactose and dibasic calcium phosphate, the authors investigated the effects of lubricant level, lubrication time, and compression speed on tablet weight, hardness, and friability.
Advertisement
Articles in this issue
over 25 years ago
Viral Clearance Strategies for Biopharmaceutical Safetyover 25 years ago
Outsourcing Outlookover 25 years ago
Managing Risks and Resourcesover 25 years ago
Blister News: COC Resin, Foil, and Lidding Innovationsover 25 years ago
Managing the Risks in Outsourcingover 25 years ago
Systemic Drug Delivery via the Buccal Mucosal RouteAdvertisement
Related to this article
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
This week, the FDA opened applications for its Expedited IND Pilot, quality experts presented at the PDA/FDA Joint Regulatory Conference, and Hovione expanded its spray drying capacity.
Christy Owings, Thermo Fisher, explains clinical trial supply chain risks in Latin America, importer-of-record strategy, AI, and eCOA delays.
Andrew Parker, PhD, executive drug development consultant, Quotient Sciences, explains how AI is integrated into pharmaceutical development.
The recently opened NJ spray drying facility doubles capacity for amorphous solid dispersions, addressing solubility limits in roughly 70% of small-molecule pipelines.
FDA opens applications for its Expedited IND Pilot, pairing sponsors with qualified research institutions to test rolling CMC review ahead of first-in-human trials.
Sanofi will transfer 20 mature medicines and three manufacturing sites to Cheplapharm for a 26.4% equity stake, closing by Q3 2027.
Advertisement
Advertisement